1. A polypeptide comprising a domain CnaBE3 SdrE, wherein the polypeptide does not contain (1) full-length protein SdrE or (2) the amino acid sequence of formula V.2. A polypeptide comprising a fragment of the protein SdrE S.aureus, wherein (a) the fragment includes a domain CnaBE3 SdrE (B) the polypeptide does not contain the full length protein SdrE and (c) the polypeptide contains the amino acid sequence of formula V.3. The polypeptide of claim 2, wherein the protein SdrE identical to SEQ ID NO:. 3 at 90% or bolee.4. The polypeptide of any one of 1-3 where CnaBE3 domain is at least 95% identical to SEQ ID NO: 8.5. The polypeptide of any one of 1-3, comprising SEQ ID NO: 8 or SEQ ID NO: 27.6. The polypeptide of any one of 1-3, which when administered to humans or mice causes the production of antibodies recognizing an epitope in SEQ ID NO: 8 or SEQ ID NO: 27.7. The polypeptide of any one of 1-3, having less than 500 aminokislot.8. A polypeptide comprising a mutant domain CnaBE3 SdrE S.aureus, where: - in one or more than one amino acid position where the native domain CnaBE3 SdrE S.aureus has asparagine residue, the mutant has either (1) a deletion of amino acids, or (2) amino acid substitution and / or- at one or more than one amino acid position where the native domain CnaBE3 SdrE S.aureus has an aspartate residue, the mutant has either (1) a deletion of amino acids, or (2) amino acid substitution and / or- at one or more than one amino acid position where the native domain CnaBE3 SdrE S.aureus has a lysine residue, whether mutant of (1) a deletion of amino acids, or (2) replace aminokisloty.9. The polypeptide of claim 8 comprising any of SEQ ID NO:. 9-26.10. A polypeptide comprising a domain CnaB S.aureus, wherein the domain comprises CnaB isopeptide svyaz.11. The polypeptide of claim. 10 wherein CnaB S.aureus domain derived from SdrE S.aureus.12. The polypeptide of claim. 11 wherein CnaB S.aureus domain is domain CnaBE3.13. A polypeptide comprising at least t
